The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands

Netherlands Journal of Medicine

Volumn 70, Issue 6, 2012, Pages 272-277

  Connolly, M P ^a,b   Boersma, C ^a   Oldenburg, B ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Global Market Access Solutions   (Switzerland)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cost effectiveness analysis; Economic evaluation; Maintenance therapy; Mesalazine; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BECLOMETASONE; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; PLACEBO; PREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; COST BENEFIT ANALYSIS; DISEASE SEVERITY; HUMAN; MAINTENANCE THERAPY; NETHERLANDS; OUTCOME ASSESSMENT; REMISSION; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; HUMANS; MESALAMINE; NETHERLANDS;

EID: 84871688442     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental influences. Gastroenterology. 2004;126:1504-1517.
2. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006; 101:1274-1282.
3. Travis SP, Stange EF, Lémann M, et al. European evidence-based Consensus on the anagement of ulcerative colitis: Current Management. J Crohns Colitis. 2008;2:24-62.
4. Bodger K. Cost effectiveness of treatments for inflammatory bowel disease. Pharmacoeconomics. 2011; 29: 387-401.
5. College voor zorgverzekeringen (CVZ). A background study on the 'cost effectiveness' package principle for the benefit of the appraisal phase in package management. Publication number 291. 05 March 2012, Available from: http://www.cvz.nl/binaries/content/documents/cvzinternet/en/documents/assessments/asm1011-cost-effectiveness-principle.pdf.
6. Koopmanschap MA. The Drug Budget Silo Mentality: The Dutch Case. Value in Health. 2003;6:S46-S51.
7. Connolly MP, Nielsen SK, Currie CJ, Marteau P, Probert CS, Travis SP. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. J Crohns Colitis. 2009;3:168-174.
8. Connolly MP, Nielsen SK, Currie CJ, Poole CD, Travis SP. An economicevaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohns Colitis. 2009;3:32-37.
9. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value in Health. 2009;12:409-418.
10. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study. Gut. 2005;54:960-965.
11. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92 1894-1898.
12. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:762-769.
13. Centraal BegeleidingsOrgaan (CBO). Richtlijn diagnostiek en behandeling van inflammatoire darmziekten bij volwassenen/ concensus: Diagnosis and treatment of IBD in adults. Nederlandse Vereniging van Maag-Darm- Leverartsen 2009, [ISBN 978-90-8523-196-7].
14. Lennard-Jones JE, Longmore AJ, Newell AC, Wilson WE, Avery Jones F. An assessment of prednisone, salazopyrin and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut. 1960;1:217-222.
15. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
16. Oostenbrink JB, Bouwmans CA, Koopmanschap MA, Rutten FF. Guideline for costing research; methods and guideline rates for economic evaluation [in Dutch]. Diemen, the Netherlands: Health Insurance Board; 2004.
17. Official Dutch Drug Prices: G-standard of Z-index; The Hague 2010 [in Dutch]. Accessed by http://www.z-index.nl/.
18. College voor zorgverzekeringen (CVZ). Guidelines for pharmacoeconomic research, updated version Valid from April 1st 2006. Series number 25001605 (2006).
19. Poole CD, Connolly MP, Nielsen SK, Currie CJ, Marteau P. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohns Colitis. 2010;4:275-282.
20. Stinnett AA, Mulahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak. 1998;18:S68-S80.
21. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53:1471-1478.
22. Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Aliment Pharmacol Ther. 2008;28:1287-1296.
23. Harris MS, Lichtenstein GR. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2011;33:996-1009.
24. Manninen P, Karvonen AL, Huhtala H, Rasmussen M, Collin P. The epidemiology of inflammatory bowel diseases in Finland. Scand J Gastroenterol. 2010;45:1063-1067.
25. Brereton N, Bodger K, Kamm MA, Hodgkins P, Yan S, Akehurst R. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. J Med Econ. 2010;13:148-161.
26. van Staa TP, Card T, Logan RF, Leufkens HGM. 5-Aminosalicy late use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-158.
27. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
28. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719-728.
29. Juan J, Estiarte R, Colomé E, Artés M, Jiménez FJ, Alonso J. Burden of illness of Crohn's disease in Spain. Dig Liver Dis. 2003;35:853-861.
30. Yen EF, Kane SV, Ladabaum U. Cost-Effectiveness of 5-Aminosalicylic Acid Therapy for Maintenance of Remission in Ulcerative Colitis. Am J Gastroenterol. 2008;103:3094-3105.